Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.43 +3.24%

+$0.01 today

Market cap
$69.91M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.24M

Average 19.76M

GOSS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Gossamer Bio, Inc.NASDAQ: GOSS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 98.6%

Gross margin was 98.6% in Q1 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 99.6%, down 0.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.6%-1.4 pp QoQ
Last fiscal yearDec 2025
97.9%-2.1 pp YoY
LTMMar 2026
99.6%-0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.4 pp——
1 year-2.1 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
97.9%
Year-over-year change
-2.1pp

Gross Margin vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 gross margin of 99.6% is the highest of the 7 companies compared; the peer median is 69.4%.
  • Its year-over-year change of -0.4 pp is the 4th highest of 6, against a peer median of +3.7 pp.
GOSS Competitors Peer median
Gross Margin for GOSS and competitors
Company Period LTM level YoY 3-year change
GOSSGossamer Bio, Inc.LTM Mar 202699.6% -0.4 pp—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202592.0% ——
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding GOSS) 69.4%+3.7 pp+36.5 pp

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.